EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Osteoradionecrosis After Modern Radiotherapy for Oral Cavity Cancer: Incidence and Risk Factors

Alyssa Farley, Taylor Petery, Nigel Dick, Jonathan Sackett, Jordan Kharofa, Vinita Takiar

Laryngoscope Investigative Otolaryngology · 2026-06 · 11 (3)

DOI: 10.1002/lio2.70431 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Objectives Osteoradionecrosis (ORN) incidence after head and neck cancer (HNC) directed radiation therapy has recently been reported to be 1%–40%. The objective of this study is to establish contemporary incidence of ORN for patients treated with IMRT exclusively for oral cavity squamous cell carcinoma (OCSCC). Methods This study is a retrospective chart review of 172 patients treated for OCSCC at a single institution from 2013 to 2022. All patients received adjuvant radiation with or without chemotherapy. Patient charts were reviewed to identify ORN. ORN was defined as exposure of bone with radiographic findings and/or physical exam findings. Data collected including age, gender, smoking status, AJCC 8th edition stage, mandibulectomy or maxillectomy as part of surgery, hospitalization in between surgery and RT, and concurrent chemotherapy. Results Mean follow up for the entire cohort was 46.1 months. The incidence of ORN in our cohort of patients was 24% at 3 years. 51.5% of patients underwent mandibulectomy or maxillectomy prior to radiation. 28.4% of patients with mandibulectomy or maxillectomy developed ORN. 18.1% of the patients treated without mandibulectomy or maxillectomy went on to develop ORN. Hazard ratio for development of ORN when patients underwent mandibulectomy or maxillectomy was 1.93. Conclusion ORN development is higher in oral cavity SCC when compared to published ORN rates in mixed HNC cohorts. Mandibulectomy and/or maxillectomy as part of surgical treatment for OCSCC increases risk for ORN development. Level of Evidence Level 3.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →